{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-23-000043","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2023-07-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.667079+00:00","generated_at":"2026-06-13T04:59:18.977052+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NovoCure PANOVA-3 pancreatic cancer trial passes interim DMC review; continues to final analysis","bullets":["Independent DMC recommended continuation of phase 3 PANOVA-3 trial for unresectable, locally advanced pancreatic cancer.","Trial evaluating TTFields plus nab-paclitaxel/gemcitabine is fully enrolled; final data expected in 2024.","No efficacy or safety data disclosed; trial proceeds as planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-23-000043","json":"https://secwatch.observer/filing/0001645113-23-000043.json","markdown":"https://secwatch.observer/filing/0001645113-23-000043.md","text":"https://secwatch.observer/filing/0001645113-23-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000043/0001645113-23-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000043/nvcr-20230721.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T04:59:18.977052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}